NEW YORK, June 29, 2026
Nuvation Bio has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co., Ltd. for taletrectinib, an investigational next-generation ROS1 inhibitor for the treatment of advanced ROS1-positive non-small cell lung cancer (NSCLC) in the United Kingdom. The application was submitted through the International Recognition Procedure (IRP), an accelerated regulatory pathway that enables the MHRA to leverage assessments conducted by trusted international regulatory authorities to facilitate faster access to innovative medicines. The validation marks another important regulatory milestone for taletrectinib, following the European Medicines Agency’s validation of its MAA earlier this year and reinforcing the therapy’s expanding global regulatory momentum. If approved, taletrectinib has the potential to provide patients with a highly selective, central nervous system (CNS)-active targeted therapy designed to address one of the most challenging forms of advanced lung cancer while expanding treatment availability across Europe and additional international markets.
Regulatory Progress Strengthens Global Access Strategy
The United Kingdom submission represents another significant milestone in the ongoing collaboration between Nuvation Bio and Eisai, which entered into an exclusive licensing agreement in January 2026 covering Europe and multiple international territories outside the United States, China, and Japan. Taletrectinib, marketed as IBTROZI® in the United States and Japan, has already demonstrated significant regulatory success, including U.S. FDA approval for patients with locally advanced or metastatic ROS1-positive NSCLC following Priority Review and Breakthrough Therapy Designations. The therapy has also received regulatory approvals in Japan and China, supporting its growing international adoption.
Additional regulatory submissions are planned across Canada and other licensed territories, reflecting the companies’ long-term strategy to make this precision oncology therapy available to eligible patients worldwide. Approximately 2% of patients diagnosed with NSCLC harbor ROS1 gene rearrangements, and a substantial proportion develop brain metastases, making CNS-active targeted therapies an important advancement in precision cancer treatment.
Clinical Evidence Demonstrates Promising Precision Oncology Potential
Advertisement
The regulatory application is supported by comprehensive clinical evidence generated through the Phase 2 TRUST-I and TRUST-II clinical studies, which evaluated taletrectinib in patients with advanced ROS1-positive NSCLC across global treatment centers. Results from pooled analyses of the TRUST clinical program have demonstrated encouraging efficacy and safety outcomes, with updated findings presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 and published in the Journal of Clinical Oncology, providing additional evidence supporting the therapy’s clinical benefit. Beyond the ongoing regulatory reviews, Nuvation Bio continues to expand the clinical development program through TRUST-IV, a global Phase 3 trial evaluating taletrectinib as an adjuvant treatment for early-stage resected ROS1-positive NSCLC, as well as TRUST-III, a randomized Phase 3 study comparing taletrectinib with crizotinib in treatment-naïve patients.
The company’s continued investment in targeted precision oncology reflects the growing importance of molecularly guided therapies that address specific genetic drivers of cancer while improving outcomes for patients with difficult-to-treat malignancies. As global regulatory reviews continue, Nuvation Bio’s progress with taletrectinib highlights the rapid evolution of precision medicine for lung cancer, offering hope for patients living with advanced ROS1-positive NSCLC through innovative therapies designed to provide durable disease control, improved CNS activity, and expanded treatment options across international healthcare systems.
Source: Nuvation Bio press release
